Glenmede Investment Management’s Mirum Pharmaceuticals MIRM Stock Holding History

Glenmede Investment Management’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$243K	Buy	+3,315	New	+$211K	﹤0.01%	1196

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Glenmede Investment Management's MIRM Position: Q3 2025 in Review

Glenmede Investment Management opened a new position in Mirum Pharmaceuticals (MIRM) in Q3 2025: 3,315 shares worth $243K. The stake represents ﹤0.01% of the portfolio and ranks #1196 among its holdings.

272 funds tracked by Wall St. Rank hold MIRM as of Q3 2025.

Glenmede Investment Management held 3,315 shares of Mirum Pharmaceuticals worth $243K as of Q3 2025.
Mirum Pharmaceuticals was a new Glenmede Investment Management position in Q3 2025.
Mirum Pharmaceuticals made up ﹤0.01% of Glenmede Investment Management's portfolio in Q3 2025, its #1196 holding.
272 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.